Apurinic/apyrimidinic endonuclease 1 (APE1/Ref‐1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion

• DOI: 10.1002/mc.22670
• Publication Date: 2017-05-03T12:42:44Z
• Authors: Manuela Juhnke; Asmus Heumann; Viktoria Chirico; Doris Höflmayer; Anne Menz; Andrea Hinsch; Claudia Hube‐Magg; Martina Kluth; Dagmar S. Lang; Christina Möller‐...; Guido Sauter; Ronald Simon; Burkhard Beyer; Raisa Pompe; Imke Thederan; Thorsten Schlomm; Andreas M. Luebke
• Keywords: Male; Oncogene Proteins, Fusion; Serine Endopeptidases; Prostatic Neoplasms; Middle Aged; Prognosis; Immunohistochemistry; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Transcriptional Regulator ERG; Tissue Array Analysis; Biomarkers, Tumor; DNA-(Apurinic or Apyrimidinic Site) Lyase; Humans; Neoplasm Grading; Aged

Polymorphisms of the base excision repair gene APE1 may be associated with an increased risk for developing prostate cancer. In other cancer types, altered APE1 protein expression is a candidate prognostic marker. Using immunohistochemistry, we thus analyzed APE1 expression in 9763 prostate cancers in a tissue microarray (TMA) with attached clinical and molecular data. The comparison with normal prostate tissue revealed an upregulation of APE1 in cancer samples. APE1 immunostaining was considered weak in 20.2%, moderate in 36.7%, and strong in 33.4% of cancers. Strong APE1 expression was markedly more frequent in prostate cancers harboring the TMPRSS2:ERG fusion (52.9%) than in ERG‐negative cancers (19.1%, P < 0.0001). Significant associations with Gleason grade, tumor stage, tumor grade, and early biochemical recurrence (P < 0.0001 each) were largely limited to ERG‐negative tumors. Multivariable analysis revealed that the prognostic value of APE1 upregulation in ERG‐negative prostate cancers was independent from established histopathological and clinical parameters. In conclusion, the results of our study demonstrate that APE1 overexpression is an independent prognostic marker, but exclusively in ERG‐negative prostate cancers.